81 |
Bariatric Surgery for Obesity: A Systematic Review and Meta-analysisAlobaid, Abdulhakeem M. January 2013 (has links)
Obesity is the fifth leading cause of global deaths. The efficacy and safety of obesity treatment is still controversial. The objective of the thesis is to evaluate the efficacy and safety of bariatric surgery, through a systematic review of the current evidence and meta- analysis of important outcomes. Nineteen (19) randomized controlled trials (RCTs) with 1346 participants were included. Bariatric surgery resulted in greater weight loss when compared to non-surgical treatment. Weight loss was also associated with resolution and/or improvement of obesity related comorbidites such as diabetes, hypertension, hyperlipidemia, and sleep apnea. Weight loss and safety varied across the surgical procedures. Biliopancreatic diversion/duodenal switch had the greatest weight loss, followed by sleeve gastrectomy and Roux-en-Y gastric bypass, purely restrictive procedures such as vertical banded gastroplasty and adjustable gastric banding resulted in the least weight loss. Long term, high quality, and adequately powered trials are still needed to support the available evidence
|
82 |
Attitudes Toward Hormone Replacement Therapy in the New Millennium: University Physicians' and Patients' PerspectivesIsmail, Hassan M., Aleveritis, Ellie, Guha, Bhuvana, Olive, Kenneth, Sloan, Susan 01 January 2005 (has links)
Background: Recent studies are changing the way physicians and patients view hormone replacement therapy (HRT). This study was performed at the East Tennessee State University (ETSU) internal medicine clinic to evaluate the current behaviors of university physicians and patients with respect to HRT. Methods: A retrospective chart review was conducted at the main internal medicine outpatient clinic at ETSU. Two hundred seventy-four postmenopausal female patients were randomly selected using a computerized systematic sampling technique of International Classification of Diseases, Ninth Revision (ICD-9) codes for menopause or postmenopause. The study period was from July 2002 until June 2004. Patients were postmenopausal women age 35 years or over who had been seen by their physicians at least twice a year during the study period. Patients who were noncompliant with HRT or physician's visits or had contraindications or side effects to HRT mandating discontinuation of the treatment were excluded. Data regarding physicians' patterns in discussion and discontinuation of the therapy and patients' responses were collected. Epi Info 2002 was used for statistical analysis. Results: One hundred seventy-seven patients met all of the criteria, of whom 140 were 35 to 75 years of age. Of this age group, 49 patients (35%) had coronary artery disease (CAD), 101 (72.1%) were on HRT prior to July 2002, and 30 (21.4%) had osteoporosis. Seventy-five patients (53.6%) had documented discussions with their physicians about HRT after July 2002. Most patients who were on HRT had no CAD (p = .0008). Of the patients who were on HRT, only 36 (35.6%) continued treatments (23 continued the same dose, and 13 had the dose modified), whereas 65 (64.3%) had treatments discontinued. HRT discussions were carried on mostly when patients had treatments stopped or modified (p = .0032). Of these patients who had discussions, 60 (80%) were advised to stop or modify the dose and agreed, and only 15 (20%) disagreed or received unbiased discussions from their physicians about HRT. Thiry-seven patients were over 75 years of age. This older group had a higher rate of HRT discontinuation (82%) but a lower rate of documented discussion (22%) than the younger group. Conclusion: Physicians should pay more attention to the importance of providing high-quality and well-balanced patient counseling when addressing uncertain treatments and adequately document discussions with patients in medical records.
|
83 |
Treatment of Hypertriglyceridemia with Omega-3 Fatty Acids: A Systematic ReviewLewis, Amanda Gloria 29 June 2004 (has links) (PDF)
Purpose: To 1) critically appraise available randomized controlled trials (RTCs) addressing the efficacy of long-chain ω-3 fatty acids as a secondary prevention agent of hypertriglyceridemia, and 2) make recommendations for clinical practice.
Data Sources: All RCTs identified from several databases from 1993-2003 were reviewed by two independent reviewers who extracted data from each study and used the previously tested Boyack and Lookinland Methodological Quality Index (MQI) to determine study quality.
Results: Ten studies reported long-chain ω-3 fatty acids to be effective in the treatment of hypertriglyceridemia. The average decrease in triglycerides (TG) was 29%, total cholesterol (TC) 11.6%, very low density lipoprotein (VLDL) 30.2%, and low-density lipoprotein (LDL) 32.5%. One study found LDLs to increase by 25%. The average increase in high-density lipoprotein (HDL) was 10%. The overall average MQI score was 36% (26%-54%). Many of the RCTs had serious shortcomings including short duration, lack of a power analysis, no intention to treat analysis, no report of blind assessment of outcome, and lack of dietary control as a confounding variable.
Conclusions/Implications: Overall study methodology was weak. Although the evidence supporting the use of long-chain ω-3 fatty acids in the secondary prevention of hypertriglyceridemia is reasonably strong, until there are larger RCTs of stronger methodological quality, it is not recommended to treat hypertriglyceridemia with ω-3 fatty acid supplementation in lieu of lipid lowering medications.
|
84 |
Oxidised LDL activates blood platelets through CD36/NOX2-mediated inhibition of the cGMP/protein kinase G signalling cascadeMagwenzi, S., Woodward, C., Wraith, K.S., Aburima, A., Raslan, Z., Jones, Huw S., McNeil, C., Wheatcroft, S., Yuldasheva, N., Febbriao, M., Kearney, M., Naseem, K.M. 29 April 2020 (has links)
No / Oxidized low-density lipoprotein (oxLDL) promotes unregulated platelet activation in dyslipidemic disorders. Although oxLDL stimulates activatory signaling, it is unclear how these events drive accelerated thrombosis. Here, we describe a mechanism for oxLDL-mediated platelet hyperactivity that requires generation of reactive oxygen species (ROS). Under arterial flow, oxLDL triggered sustained generation of platelet intracellular ROS, which was blocked by CD36 inhibitors, mimicked by CD36-specific oxidized phospholipids, and ablated in CD36(-/-) murine platelets. oxLDL-induced ROS generation was blocked by the reduced NAD phosphate oxidase 2 (NOX2) inhibitor, gp91ds-tat, and absent in NOX2(-/-) mice. The synthesis of ROS by oxLDL/CD36 required Src-family kinases and protein kinase C (PKC)-dependent phosphorylation and activation of NOX2. In functional assays, oxLDL abolished guanosine 3',5'-cyclic monophosphate (cGMP)-mediated signaling and inhibited platelet aggregation and arrest under flow. This was prevented by either pharmacologic inhibition of NOX2 in human platelets or genetic ablation of NOX2 in murine platelets. Platelets from hyperlipidemic mice were also found to have a diminished sensitivity to cGMP when tested ex vivo, a phenotype that was corrected by infusion of gp91ds-tat into the mice. This study demonstrates that oxLDL and hyperlipidemia stimulate the generation of NOX2-derived ROS through a CD36-PKC pathway and may promote platelet hyperactivity through modulation of cGMP signaling. / the British Heart Foundation (PG/11/37/28884 and PG/13/90/30578) and Heart Research UK (RG2614)
|
85 |
Measurement of Blood Lipids using Flow Cytometry and Spectrophotometry / Mätning av Blodlipider med Flödescytometri och SpektrofotometriRos Thorisdottir, Yrsa January 2024 (has links)
Hematology analyzers can be used for screening patients for blood abnor-malities. The techniques used in a hematology analyzer include impedanceanalysis, flow cytometry and spectroscopy, which allow for measuring of forexample absolute count, sizes and concentration of different cells in a patient’sblood sample. Hyperlipidemia, which refers to elevated blood lipid levels, isthe primary cause of heart-related illness and fatalities in today’s developedor developing countries. Currently, blood lipid levels are not measured as aparameter with hematology analyzers. Since hematology analyzers allow for arapid general screening of blood parameters, an area of interest is therefore tobe able to measure blood lipids with a hematology analyzer. Thus, this studyaims to investigate the possibility of detecting and measuring blood lipids witha hematology analyzer, using flow cytometry and/or spectrophotometry. In order to investigate this possibility, two simulating methods were conductedwhere in the first method Intralipid 20% was mixed with saline into sampleswith different lipid concentrations. In the second method, diluent wasused instead of saline. Lastly a Correlation study was performed whereIntralipid 20% was mixed with donor blood to prepare samples with differentlipid concentrations. All samples were then analyzed in a hematologyanalyser and scatter plots from flow cytometry and light absorption datafrom spectrophotometry measurements were obtained. The methods showedthat there is a strong correlation between number of detected pulse countsfrom the scatter plots and lipid concentration. Same applies to lightabsorption compared to the lipid concentration of the samples, measured withspectrophotometry. The results from this study show that it is in fact possible to detect andmeasure blood lipid levels with a hematology analyser using flow cytometryand spectrophotometry. Further development within this area could thereforeenable simple screening of this additional parameter and early detection ofindications of hyperlipidemia. / Hematologianalysatorer möjliggör screening av eventuella avvikelser ipatienters blood. De tekniker som används i en hematologianalysatorinkluderar impedansanalys, flödescytometri och spektroskopi, vilka möj-liggör mätning av till exempel absolutantal, storlekar och koncentrationav olika celler i ett patientblodprov. Hyperlipidemi, vilket hänvisar tillförhöjda blodlipidnivåer, är den främsta orsaken till hjärtrelaterade sjukdomaroch dödsfall i dagens utvecklade eller utvecklingsländer. För närvarandemäts inte blodlipidnivåer som en parameter med hematologianalysatorer.Eftersom hematologianalysatorer möjliggör en snabb allmän screening avblodparametrar, är ett intresseområde därför att kunna mäta blodlipider meden hematologianalysator. Syftet med denna studie är därför att undersökamöjligheten att detektera och mäta blodlipider med en hematologianalysator,med hjälp av flödescytometri och/eller spektrofotometri. Två simuleringsmetoder genomfördes, där den första metoden innefattadeblandning av Intralipid 20% med saltlösning till prover med varierandelipidkoncentration. I den andra metoden användes spädningsvätska iställetför saltlösning. Slutligen genomfördes en korrelationsstudie där Intralipid20% blandades med donatorblod och prover med olika lipidkoncentrationerförbereddes. Alla prover analyserades sedan i en hematologianalysator ochspridningsdiagram och ljusabsorptionsdata från spektrofotometrimätningarerhölls. Resultaten visade att det finns en stark korrelation mellan antalet de-tekterade pulsräkningar från spridningsdiagrammen och lipidkoncentrationen.Samma gäller för ljusabsorption jämfört med lipidkoncentrationen i proverna,mätt med spektrofotometri. Resultaten från denna studie visar att det faktiskt är möjligt att detektera ochmäta blodlipidnivåer med en hematologianalysator med hjälp av flödescyto-metri och spektrofotometri. Vidare utveckling inom detta område skulle därförkunna möjliggöra enkel screening av patienters blod lipidkoncentration samtunderlätta en tidig upptäckt av indikationer på hyperlipidemi.
|
86 |
"Antilipoproteína lipase (LPL): um novo componente no complexo processo aterosclerótico do lúpus eritematoso sistêmico?" / Antilipoprotein lipase antibodies (aLPL): a new player in the complex atherosclerotic process in systemic lupus erythematosus?Carvalho, Jozélio Freire de 15 August 2005 (has links)
Dislipidemia é implicada no processo aterosclerótico do LES. A descrição de aLPL no LES associado a hipertrigliceridemia levou-nos a analisar esse anticorpo no contexto da inflamação envolvida na aterogênese. aLPL foi encontrado em 38% dos pacientes com LES com altos níveis de triglicérides. Correlação positiva significante foi observada entre aLPL e PCR, VHS, SLEDAI, anti-DNA, anti-cardiolipina e CH100 baixo. Análise de regressão múltipla confirmou a forte associação entre aLPL e PCR. Esses dados dão suporte à associação entre inflamação, resposta imune e dislipidemia, introduzindo o aLPL como um novo componente nos complexos eventos da aterogênese do LES / Dyslipidemia is implicated in the atherosclerosis process of SLE. The description of aLPL in SLE associated with hypertrigliceridemia prompted us to analyze this antibody in the context of the inflammation involved in the atherogenesis. aLPL was found in 38 por cento of SLE patients with high levels of triglycerides. Significant positive correlation was observed between aLPL and CRP, ESR, SLEDAI, anti-DNA, anti-cardiolipin and low CH100. Multiple regression analysis confirmed the strong association between aLPL and CRP. These data support the link between inflammation, immune response and dyslipidemia, introducing anti-LPL as new player in the complex events of atherogenesis in SLE
|
87 |
"Antilipoproteína lipase (LPL): um novo componente no complexo processo aterosclerótico do lúpus eritematoso sistêmico?" / Antilipoprotein lipase antibodies (aLPL): a new player in the complex atherosclerotic process in systemic lupus erythematosus?Jozélio Freire de Carvalho 15 August 2005 (has links)
Dislipidemia é implicada no processo aterosclerótico do LES. A descrição de aLPL no LES associado a hipertrigliceridemia levou-nos a analisar esse anticorpo no contexto da inflamação envolvida na aterogênese. aLPL foi encontrado em 38% dos pacientes com LES com altos níveis de triglicérides. Correlação positiva significante foi observada entre aLPL e PCR, VHS, SLEDAI, anti-DNA, anti-cardiolipina e CH100 baixo. Análise de regressão múltipla confirmou a forte associação entre aLPL e PCR. Esses dados dão suporte à associação entre inflamação, resposta imune e dislipidemia, introduzindo o aLPL como um novo componente nos complexos eventos da aterogênese do LES / Dyslipidemia is implicated in the atherosclerosis process of SLE. The description of aLPL in SLE associated with hypertrigliceridemia prompted us to analyze this antibody in the context of the inflammation involved in the atherogenesis. aLPL was found in 38 por cento of SLE patients with high levels of triglycerides. Significant positive correlation was observed between aLPL and CRP, ESR, SLEDAI, anti-DNA, anti-cardiolipin and low CH100. Multiple regression analysis confirmed the strong association between aLPL and CRP. These data support the link between inflammation, immune response and dyslipidemia, introducing anti-LPL as new player in the complex events of atherogenesis in SLE
|
88 |
Efeitos do aconselhamento nutricional em pacientes dislipidemicos segundo sexo, idade e tempo de tratamento / Effects of nutritional counseling on dyslipidemic patients according to sex, age and treatment timeKinchoku, Harumi 13 December 2007 (has links)
Orientador: Eliana Cotta de Faria / Dissertação (mestrado) - Universidade Estadual de Campinas, Faculdade de Ciencias Medicas / Made available in DSpace on 2018-08-10T15:03:58Z (GMT). No. of bitstreams: 1
Kinchoku_Harumi_M.pdf: 2499549 bytes, checksum: e5ef36d494fba41f42bf6fe5ac2c96dc (MD5)
Previous issue date: 2007 / Resumo: Os principais determinantes da dieta que elevam as concentraçoes de LDL-C sao as gorduras saturadas, gorduras trans e, em menor grau, o colesterol da dieta. O aumento relativo na proporçao de carboidratos resulta em dislipidemia caracterizada pelo aumento das concentrações plasmáticas de TG e VLDL-C, baixas concentrações de HDL-C, razão C:HDL aumentada e, algumas vezes, a presença de partículas de LDL-C pequenas e densas.O propósito deste estudo foi avaliar o impacto do aconselhamento nutricional exclusivo em portadores de dislipidemias,verificando a resposta entre sexos e entre faixas etárias (<60 anos e = 60 anos) e a influência do tempo no tratamento (3,6 e 12 meses). Participaram do estudo 129 sujeitos, 56 homens e 73 mulheres com idade entre 20 a 73 anos sem uso de medicaçao hipolipemiante por no mínimo 30 dias antes e durante o tratamento, e com pelo menos três meses de seguimento nutricional. Para hipercolesterolemia foi orientada a restrição de gorduras saturadas (<7% do VET) e colesterol (<200 mg/dL) e, para hipertrigliceridemia a restriçao de carboidratos simples, bebidas alcoólicas e, restrição de gorduras totais (<20% do VET) para TG>300 mg/dL. Na presença de sobrepeso ou obesidade foi orientada dieta hipocalórica com redução gradativa das calorias. As concentrações de colesterol (C), LDL-C, e triglicérides (TG) foram significativamente reduzidas na população estudada em 14%, 5%, 30% respectivamente. No primeiro trabalho, em que foi avaliada a influência do tempo de aconselhamento nutricional comparado ao período basal, as respostas significativas às orientações dietéticas com três meses foram: para C (-16%), LDL-C (-0,1%) e não HDL-C (-19%); com seis meses para C (-13%), TG (-30%), LDL-C (-9%), nao HDL-C (-17%), Castelli I (-14%) e Castelli II (-4%) e, com 12 meses para C (-14%), TG (-27%) e Castelli I (-13%). As concentrações plasmáticas de HDL-C e o peso corporal não se modificaram. Entre os sexos (trabalho 2) foi observado uma redução de 16% para C e 36% para TG em homens, e de 12% para C, 12% para LDL-C, e 26% para TG nas mulheres e, entre faixa etária de 15% para C, 2% para LDL-C e 33% para TG nos adultos e 14% para C nos idosos. O aumento na concentração de HDL-C foi significativa em homens em relação às mulheres (+5% e -4 %) com hiperlipidemia mista.Todos os participantes responderam ao aconselhamento nutricional reduzindo as concentrações de C, TG, LDL-C e a nao HDL-C. O tempo de orientação dietética não modificou as respostas em lípides e lipoproteínas plasmáticos; sendo o tempo de três meses suficiente para observar os efeitos benéficos da dieta. Um maior número de parâmetros foi reduzido com seis meses indicando que a partir de sexto mês houve um efeito mais abrangente da dieta. Homens e adultos foram mais responsivos à orientação nutricional. As respostas foram maiores que os coeficientes de variação biológico para cada parâmetro avaliado exceto para LDL-C.Recomenda-se a aplicação desta experiência terapêutica positiva em outros Serviços de Saúde por se tratar de uma terapia de baixo custo podendo também contribuir na prevenção e controle de doença cardiovascular / Abstract: The strongest dietary determinants of elevated LDL cholesterol concentrations are dietary saturated fatty acid and trans fatty acid intakes to a lesser extent, dietary cholesterol and excess body weight The aim of the present study was to evaluate the responses plasma lipid to nutritional counseling on dyslipidemic outpatients and analyze their responses by gender and age and analyzing the influence of time (3, 6 and 12 months) of treatment. One-hundred and twenty nine dyslipidemic subjects i.e. 56 males and 73 females aged 20 - 73 years comprised this study. No medication was used 30 days before and during following the diet as part of the inclusion criteria. Patients with hypercholesterolemia were oriented to follow the NCEP step 2 diet, and those with hypertriglyceridemia were oriented to restrict simple carbohydrates and alcoholic beverage and, in presence of TG >300 mg/dl, to use low fat diet (=20%). After nutritional counseling plasma cholesterol (C) concentrations, LDL-C, and triglycerides (TG) were significantly reduced in the population sample by (14%, 5%, 30%), respectively. The response were significant after 3 months for C (-16%), LDL-C (-0,1%) and NHDL-C (-19%), after 6 months for C (-13%), TG (-30%), LDL-C (-9%), NHDL-C (-17%), Castelli I (-14%) and Castelli II (-4%) and, after 12 months for C (-14%), TG (-27%) and Castelli I (-13%). No change was detected in plasma HDL-cholesterol and body weight, after nutritional counseling. Between sexes plasma concentrations reduced for C and TG by 16%, and 36% in men, and by 12% and 26% and 12% for LDL-C in women, and between age by 15% to C, 2% to LDL-C and 33% to TG in middle age and, 14% for C in elderly people. HDL cholesterol concentration was significantly higher in men than in women with mixed hyperlipidemia (+5% and -4 %). All participants responded to nutritional counseling reducing C, TG, LDL-C, NHDL-C, LDL-C. The nutritional counseling time did not modify the responses of plasma lipids and lipoproteins. After 3 months, beneficial effects of the diet were observed, and the higher number of parameters were reduced after 6 month showing a broader actions of diet. Men and adults patients presented better responses to nutritional counseling. The responses to nutritional counseling were higher than coefficient biology variation for each parameter evaluated except to LDL-C. We recommend this positive experience is recommended to other Health Service because is low cost treatment and also contribute in prevention and control of risk factors for cardiovascular disease / Mestrado / Ciencias Basicas / Mestre em Clinica Medica
|
89 |
Differences in Diet Quality and Concurrent Chronic Diseases by Level of Glycemic Control in US AdultsFanelli, Stephanie Marissa 17 June 2019 (has links)
No description available.
|
Page generated in 0.0623 seconds